| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -21.5 | -11.8 |
| Net income | -21.5 | -11.8 |
| EPS (diluted, $ a share) | $-0.13 | $-0.08 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: TRVI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Trevi Therapeutics, Inc.: key numbers
- Share price
- $13.29Close, Nov 16
- Market cap
- $1.89B
- Shares outstanding
- 142.56MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Trevi Therapeutics, Inc.
All →Trevi Therapeutics Financial Results
Trevi Therapeutics reported financial results for the third quarter of 2026, highlighting the initiation of its Phase 3 OCEAN-2 trial for IPF-related chronic cough. The company also reached alignment with the FDA on a Phase 2 development path for non-IPF ILD-related chronic cough, with a trial expected to start in Q1 2027. Trevi maintains a cash runway into 2030 to fund its key clinical milestones.
- Term
- Q3 2026
“This is an important time of clinical execution for Trevi as we actively open sites globally and enroll patients across all three active trials. We also recently aligned with the FDA on our non-IPF ILD-related chronic cough program and expect to initiate a Phase 2 dose-ranging trial in the first quarter of 2027.”
Jennifer Good, President and CEO of Trevi Therapeutics